Menopausal Hormone Therapy (MHT) is a key yet underutilized strategy for osteoporosis prevention. In this session for healthcare providers, Dr. Amanda Clark and Dr. Michael McClung will review the latest evidence on MHT’s role in bone health, including patient selection, timing, and risk-benefit considerations. Gain practical insights to optimize fracture prevention and long-term skeletal health in your patients.

Amanda Clark, MD, MCR, MSCP, FACOG, is a leader in urogynecology and pelvic reconstructive surgery. At Oregon Health and Science University (OHSU), she founded the Division of Urogynecology and Reconstructive Pelvic Surgery and established its first fellowship program. She remains actively involved in research and fellowship training, focusing on uncovering the causes of pelvic floor disorders to improve treatment options for women.

Dr. Clark is a peer reviewer for leading journals like The International Journal of Urogynecology and The American Journal of Obstetrics and Gynecology and reviews grants for the National Institutes of Health. Originally from a small town in Kentucky, she moved to Portland for her medical training and has embraced the city as home for over 25 years. Outside of her practice, Dr. Clark enjoys jazz piano, gardening, hiking, and biking while soaking in Portland’s vibrant culture and natural beauty.

Michael McClung, MD, FACP, FACE, is a globally recognized expert in osteoporosis and bone health. As the founding director of the Oregon Osteoporosis Center, he has led groundbreaking research on fracture prevention, bone density, and the role of Menopausal Hormone Therapy (MHT) in skeletal health. Dr. McClung has contributed extensively to international guidelines and continues to educate healthcare providers on evidence-based strategies for osteoporosis management.